Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.
about
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesHER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerOpen-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative mePertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival.Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Safety and efficacy evaluation of pertuzumab in patients with solid tumorsPertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan.Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancerPharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer.Pertuzumab: new hope for patients with HER2-positive breast cancer.Monoclonal antibodies in lung cancer.Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.Pertuzumab for the treatment of metastatic breast cancer.Pertuzumab for the treatment of breast cancer.Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.Pertuzumab in gastrointestinal cancer.Pertuzumab for the treatment of breast cancer: a safety review.
P2860
Q28083123-20A4B1C6-0EF6-4DF1-AD87-869F8B208E5FQ28237833-3ADEC92A-3A2D-4CC5-AA6A-0D4D6651B058Q30376023-5BF8CDF4-4C2C-4FAA-A927-25CC92733AC4Q33618685-8BA04843-5146-4859-A51A-AE4B33C95D95Q33680109-11FA1D30-26FD-4B0A-A5E0-76EF590D5CADQ33714388-D1B95B92-AA61-4BCC-82DC-9686A9729749Q36336483-7459850D-CAC3-48E8-86FE-59C6E8F6C17FQ37205749-80615B72-25A8-4012-9CFE-E48EBC1FBE3EQ37639279-7C759CEA-D0E0-405D-91FA-FE6352F26FE3Q37970020-15AF2E72-FDA3-4FAE-99A9-3E3470229365Q37982433-C2C7B727-FAED-489E-9606-7D2F95B2C9D3Q38036549-18E53523-C234-41A7-BDAF-094AABD841BBQ38067454-6070F7E5-766B-4680-8F92-F33F0277BA4BQ38119307-544B0754-0C0A-4EFA-8669-91AD28E9CE4AQ38123762-1D2EA7EB-C9B1-48FF-9472-4BD9BD579D78Q38126859-A1FFA47B-C3FE-4407-9196-851741D4C7CFQ38132047-FDF4E1E2-E013-401C-8626-C1017148F4AFQ38132237-C26DA8DE-96FA-44B3-95A1-76C9CD4F299DQ38219674-62E031F9-1B0D-40E0-B7E9-85B058E3F43EQ38286163-97E66BF1-10B2-4A9A-A397-AA4E6BB44FF5Q38364462-5F3715DF-E7D1-4A8B-B321-83A016BC7235Q38373931-F6503809-C4E6-43BB-A483-19873CF5D1F7Q38573858-101BFE5B-45BF-4AB8-B85C-C83E2F1A1FB8Q38653309-FE471D40-B57E-4BF4-9D23-9F3E441A59BAQ38776876-A2FAEE79-9A30-47CB-8CA0-9A6E095D4380
P2860
Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@en
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@nl
type
label
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@en
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@nl
prefLabel
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@en
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@nl
P2093
P2860
P356
P1476
Phase I and pharmacokinetic st ...... se patients with solid tumors.
@en
P2093
Kazuhiko Yamada
Noboru Yamamoto
Tomohide Tamura
Toshio Shimizu
Yasuhide Yamada
Yasuhito Fujisaka
Yutaka Fujiwara
P2860
P304
P356
10.1093/JJCO/HYP006
P577
2009-03-04T00:00:00Z